Abrika Pharmaceuticals

Abrika Pharmaceuticals was a specialty pharmaceutical company focused on the development of proprietary and generic controlled-release products. The company utilized advanced drug delivery technologies to create enhanced versions of existing medications, particularly in the areas of pain management and central nervous system disorders. Abrika's portfolio included a significant generic version of Concerta (methylphenidate) for the treatment of ADHD. In 2007, the company was acquired by Actavis for $110 million to bolster its specialty generic pipeline and formulation expertise. Following subsequent industry consolidations, its assets became part of Teva Pharmaceutical Industries.